skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Neoantigen-based Melanoma-Poly-ICLC Vaccine (Code C112003)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Neoantigen-based Melanoma-Poly-ICLC Vaccine

Definition: A peptide-based melanoma cancer vaccine consisting of neoantigens and peptides derived from patient-specific melanoma immunogenic epitopes, combined with the immunostimulant poly-ICLC with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-based melanoma vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. The adjuvant poly-ICLC, composed of double-stranded RNA molecules of polyinosinic-polycytidylic acid stabilized with poly L-lysine in carboxymethylcellulose, is a ligand for toll-like receptor-3 (TLR3) and induces the release of cytokines which may help to boost the immune response against the selected neoantigens.

Label: Neoantigen-based Melanoma-Poly-ICLC Vaccine

NCI Thesaurus Code: C112003 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454292  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Neoantigen-based Melanoma-Poly-ICLC Vaccine
NeoVax Melanoma Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 754239
PDQ Open Trial Search ID 754239 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C112003
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom